Adial Pharmaceuticals (ADIL) Stock Analysis

What Adial Pharmaceuticals does

Adial Pharmaceuticals, Inc. is a biopharmaceutical enterprise operating at the clinical stage, dedicated to researching and developing innovative therapeutic options for the management and prevention of addiction and associated disorders. Its primary investigational compound, AD04, functions as a selective serotonin-3 antagonist and is currently undergoing pivotal Phase III clinical trials for the treatment of alcohol use disorder. Beyond this flagship product, the company is also exploring drug candidates aimed at providing non-opioid pain relief and addressing a range of other medical conditions. Established in 2010, Adial Pharmaceuticals, Inc. is headquartered in Charlottesville, Virginia.

Key metrics

ETFs linked to ADIL

Broad-market and Healthcare sector ETFs an investor holding Adial Pharmaceuticals is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how ADIL fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Adial Pharmaceuticals?

Adial Pharmaceuticals trades under the ticker ADIL on NASDAQ.

Which exchange is ADIL listed on?

ADIL is listed on NASDAQ.

What sector does Adial Pharmaceuticals operate in?

Adial Pharmaceuticals is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze ADIL in a portfolio?

PortView shows ADIL's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.